reply:
I didnt say "buyout"..........there are in many cases "partnerships" drafted up for the "science" and to obtain "capital" for further research for drug development, and clinical trials for fda approval.
do you really think the 26 million from lincoln capital is enough to pursue all their goals for the "different" types of cancers they mention to find better drug development" or in their case the delivery tool "cell in a box"?
diabetes, breast cancer, and others besides pancreatic cancer are on their list.....
I am long but are we really replacing celgenes "gold standard" or are we supplying the delivery system for it? and what would be the cost of that delivery system? how profitable will this delivery system be? Honest question really..would love some feedback on that one.
with pills they take them daily.....run out...buy some more and offer a continuous stream of revenue for the company...........mainly the reason its more profitable to prolong cancer than to cure it<unfortunately> and thus the conspiracy theories which have some truth in them if you understand human nature.
NOW, in reply to dr. VON HOFF remark.............this is not NEW NEWS.......we already anounced that he would be an advisor for NUVILEX and we patted ourselves on the back last month about it.............Von HOFF like any doctor in his field will take a paycheck to be an advisor for a "promising" new "tool" as Von HOFF called it....to further cancer research.
So why all suprised as if its new news that they selected his CRO? wouldnt that have been the obvious next move? that still doesnt mean he works for nuvilex......its a great choice to do that....but........he is paid for his services......he didnt ask to join the nuvilex board of directors ....and says a general statement "we are excited to be working.......".....as expected by any work related press release.
I am glad WE picked VON HOFF to advise............but theres to much insinuation here.......people read into things to much and i would still LOVE to see validation or interest by big pharma for what we do or are capable of doing.
since we hold world wide rights for this "cell in the box" its not too much to expect someone like eli lilly to show interest and pay us a royalty fee to license this tech from us to do their own research.
If you play chess like I do you should always be thinking at least two or 3 moves ahead.....
I am not bashing this stock..I am glad to see a new 5 day high on it and hope to see my account continue to go up but i remain neutral on these news releases.......
if all we do is just start phase 3 and focus on that alone then that will be fine...the stock should go up in milestone announcments.......but real excitement is shown by the outside community, not the people on your payroll.
I am limited to 1 text a day and thats why i replied so late.
hopefully mmj sciences can start to grow ..........so we can have a more diversified portfolio of opportunities for nuvilex.I would suggest they start growing their own real soon like gw pharma who was on cannabis 2 and has their stock shooting straight up.
Bull durham......please replyto my previous question.............how will we make money from cell in a box if it is approved?
will we be lisencing out the tool to celgene...........will we be supplying the tool ourselves? will we be administering the shots? Are we going to make the medicine ourselves like pharma does? or are we just buying/lisencing celgenes drug and charging for our "deliovery system"? that would be a one time fee looks like since it stays in the body for up to two years....which is the lifespan we are aiming for in our clinical trials.
